1452458-86-4

Upstream product

• 1452466-19-1 {2-[({[(2S,5R)-6-benzyloxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}amino)oxy]ethyl}carbamic acid tert-butyl ester 
• 1452466-20-4 {2-[({[(2S,5R)-6-hydroxy-7-oxo-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}amino)oxy]ethyl}carbamic acid tert-butyl ester 
• 1452467-93-4 tert-butyl {2-[({[(2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}amino)oxy]ethyl}carbamate 
• 1174020-25-7 (2S,5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylic acid 
• 81470-51-1 tert-butyl N-benzyloxycarbonyl-L-pyroglutamate 
• 147489-30-3 (2S)-5-oxopiperidine-1,2-dicarboxylic acid 1-benzyl ester 2-tert-butyl ester 
• 169825-97-2 N-benzyloxycarbonyl-(2S,5S)-5-hydroxypipecolic acid tert-butyl ester 
• 1501977-14-5 {2-[({[(2S,5R)-7-oxo-6-sulphooxy-1,6-diazabicyclo[3.2.1]oct-2-yl]carbonyl}amino)oxy]ethyl}carbamic acid tert-butyl ester tetrabutylammonium 
• 32159-21-0 Cbz-L-pGlu-OH 
• 1383814-52-5 (2S,5S)-tert-butyl 5-hydroxypiperidine-2-carboxylate 
• 1383814-53-6 (2S,5S)-tert-butyl 5-hydroxy-1-(2,2,2-trifluoroacetyl)piperidine-2-carboxylate 
• 1383814-54-7 (2S,5R)-tert-butyl 5-(benzyloxyamino)-1-(2,2,2-trifluoroacetyl)piperidine-2-carboxylate 
• 1383814-55-8 (2S,5R)-tert-butyl 5-(benzyloxyamino)piperidine-2-carboxylate 
• 1383814-56-9 (2S,5R)-tert-butyl 6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate 

Relevant academic research and scientific papers

PROCESS FOR O-SULFONATION OF 1,6-DIAZABICYCLO[3.2.1]OCTANE COMPOUNDS

A process for preparation of a compound of Formula (I), or a salt thereof is disclosed.

Beta-lactamase inhibitors and uses thereof

β-Lactamase inhibiting compounds, therapeutic methods of using the β-lactamase inhibiting compounds, particularly in combination with β-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The β-lactamase inhibiting compounds are suitable for oral administration.

PRODUCTION PROCESS OF CRYSTALS OF DIAZABICYCLOOCTANE DERIVATIVE AND STABLE LYOPHILIZED PREPARATION

A process for producing crystals of a compound represented by the following formula (l): by crystallizing the compound from an aqueous solution containing the compound and an inorganic salt, such as sodium chloride. Such crystals can be subjected to lyophilization to provide a lyophilized composition having a desirable storage stability

Production method for diazabicyclooctane derivative and intermediary body thereof

The present invention provides a production method for a diazabicyclooctane derivative expressed by formula (IV), and an intermediary body thereof (in the formula: P is an acid-removable NH protective group; R1 represents a 2, 5-dioxopyrrolidine-1-yl, a 1, 3-dioxo-3a, a 4, 7, 7a-tetrahydro-1H-isoindole-2(3H)-yl, a 1, 3-dioxohexahydro-1H-isoindole-2(3H)-yl, or a 3, 5-dioxo-4-azatricyclo[5.2.1.02, 6]deca-8-en-4-yl; R2 represents hydrogen, C1CO-, or C13COCO-, R3 represents a C1-6 alkyl or a heterocyclyl, or joins with a bonded -O-NH- to form a 3-7 member heterocyclyl ring; and OBn represents a benzyloxy).

CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF

A crystalline form of a diazabicyclooctane derivative represented by the following Formula (VII), and processes for producing the same:

CRYSTAL OF DIAZABICYCLEOCTANE DERIVATE AND METHOD FOR PRODUCING THE SAME

The present invention provides a crystal of diazabicycleoctane derivate represented by the following formula (VII), especially formula (VII-1), and a method for producing the same.

A PROCESS FOR PREPARATION OF (2S, 5R)-N-(2-AMINO ETHOXY)-6-(SULFOOXY)-7-OXO-1,6- DIAZABICYCLO [3.2.1] OCTANE-2-CARBOXAMIDE

A process for preparation of (2S,5R)-N-(2-aminoethoxy)-6-(sulfooxy)-7-oxo-1,6-diaza-bicyclo[3.2.1]octane-2-carboxamide is disclosed. Formula (I)

NOVEL -LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME

The currently available β-lactamase inhibitors are insufficient to inhibit the incessantly increasing β-lactamase, and novel β-lactamase inhibitors has been required today for the difficult treatment for bacterial infectious diseases caused by resistant bacteria which produce class C β-lactamase, extended-spectrum β-lactamase (ESBL) belonging to class A and D, or class A KPC-2 decomposing even carbapenem as a last resort for β-lactam antibiotic. A compound represented by the the formula (I), preparation process of the same, β-lactamase inhibitors and method for treating bacterial infectious diseases are provided.

NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS

A compound of formula (I), wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR1 or NR2R3, and R1,R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.

NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS

A compound of formula (I): wherein: M is hydrogen or a pharmaceutically acceptable salt-forming cation; Y is OR1 or NR2R3, and R1, R2, R3 and M are as defined herein. Also, methods of treating bacterial infection, pharmaceutical compositions, molecular complexes and processes for preparing compounds.